Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT) treatment is unclear.
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy / De Angelis, Carmine; Nagi, Chandandeep; Hoyt, Cliff C; Liu, Linying; Roman, Kristin; Wang, Chichung; Zheng, Yi; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Nuciforo, Paolo; Wang, Tao; Tsimelzon, Anna; Mao, Sufeng; Hilsenbeck, Susan G; Trivedi, Meghana V; Cataldo, Maria Letizia; Pavlick, Anne; Wolff, Antonio C; Weigelt, Britta; Reis-Filho, Jorge S; Prat, Aleix; Gutierrez, Carolina; Osborne, Charles Kent; Rimawi, Mothaffar F; Schiff, Rachel. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 26:3(2020), pp. 738-745. [10.1158/1078-0432.CCR-19-1402]
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy
De Angelis, CarminePrimo
;Cataldo, Maria Letizia;
2020
Abstract
Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT) treatment is unclear.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
